Document series
Supplier dossiers
28 suppliers assessed against a published six-criterion documentation rubric. The Institute performs no independent testing.
A dossier assesses what a supplier documents, not what it sells. The Institute has purchased nothing, tested nothing and inspected nothing, and every score on these pages is a judgement about records.
The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.
No ranking is published. The comparison table sorts on any column and its default order is alphabetical; the coverage limitation of each dossier is carried in the table itself rather than behind a link, following a public submission that a reader sorting a table does not follow links first.
Suppliers the Institute has not assessed
A dossier requires enough published or supplied documentation to score six criteria. The 188 suppliers below have been identified in submitted material but do not meet that threshold, in most cases because nothing beyond a purity percentage was ever obtainable. They are listed so that the assessed set reads as a documentation threshold rather than a shortlist. No dossier, no score, no outbound link.
| Supplier | Reported band | Reports identified | Why no dossier |
|---|---|---|---|
| Trusted Peptide | B | 2 | Submitted evidence extends to 2 results and no dossier has been opened. Recorded determinations are mutually consistent. |
| Risynth Bio | B | 8 | Submitted evidence extends to 8 results, which is thin relative to catalogue breadth. Internal consistency is not in question. |
| NUPEPS Peptides | B | 4 | 4 determinations are held, below the minimum the rubric requires for a dossier. Consistent across the whole evidence base. |
| Hunan GoodPeptides Biotech Co | B | 2 | Submitted evidence extends to 2 results and no dossier has been opened. |
| Bulk Peptide Wholesale | B | 20 | 20 determinations are held — adequate to characterise, short of the threshold for assessment. The determinations cluster. |
| Paradigm Peptide | B | 16 | 16 determinations constitute a working sample rather than a testing history. The determinations cluster. |
| Orbitrex Peptides | B | 17 | At 17 determinations the central tendency is estimable and the interval is wide. |
| Aavant Research | B | 13 | At 13 determinations the central tendency is estimable and the interval is wide. Recorded determinations are mutually consistent. |
| PeptiAtlas | B | 4 | 4 determinations are held, below the minimum the rubric requires for a dossier. |
| The Naughty Needle | B | 2 | 2 determinations are on record. The Institute does not assess on that basis. |
| Lux Synth Aminos | B | 2 | The evidence base comprises 2 independent determinations, which is insufficient to support any criterion. Consistent across the whole evidence base. |
| Huaian Hanyou Peptide | B | 7 | At 7 determinations, sampling variation exceeds any effect the figures would show. No determination in the set is inconsistent with another. |
| Lisa Biopeptide | B | 11 | Submitted evidence extends to 11 results, which is thin relative to catalogue breadth. No determination in the set is inconsistent with another. |
| Lipeptides | B | 7 | 7 determinations are held, below the minimum the rubric requires for a dossier. Recorded determinations are mutually consistent. |
| NextGen Health | B | 3 | 3 determinations are on record. The Institute does not assess on that basis. Internal consistency is not in question. |
| OmegAmino | B | 4 | 4 determinations permit an impression and do not permit an assessment. Internal consistency is not in question. |
| Xianhong Tong XHT Peptides | B | 5 | The evidence base comprises 5 results and is classified as insufficient. No determination in the set is inconsistent with another. |
| Diju Peptides Wellness and Co | B | 4 | At 4 determinations, sampling variation exceeds any effect the figures would show. |
| Zhang TY | B | 4 | Submitted evidence extends to 4 results, which is thin relative to catalogue breadth. The determinations cluster. |
| SubQ Society | B | 3 | The evidence base comprises 3 independent determinations, which is insufficient to support any criterion. Consistent across the whole evidence base. |
| Bfflink | B | 13 | 13 determinations constitute a working sample rather than a testing history. No determination in the set is inconsistent with another. |
| Laicuinuo LCN | B | 7 | The evidence base comprises 7 results and is classified as insufficient. Recorded determinations are mutually consistent. |
| Cellupep | B | 7 | 7 determinations are held, below the minimum the rubric requires for a dossier. No determination in the set is inconsistent with another. |
| Shanghai Leader Peptide Biotechnology | B | 8 | 8 determinations are held, below the minimum the rubric requires for a dossier. The determinations cluster. |
| Peptronix Bio PTB | B | 13 | The evidence base comprises 13 results and has not stabilised. Internal consistency is not in question. |
| Yongkang Nuoao Trading Co | B | 9 | The evidence base comprises 9 results and is classified as insufficient. Recorded determinations are mutually consistent. |
| Eros Peptides | B | 3 | 3 determinations are on record. The Institute does not assess on that basis. The determinations cluster. |
| Champion Peptide | B | 6 | At 6 determinations, sampling variation exceeds any effect the figures would show. |
| Bio Pepz | B | 4 | Submitted evidence extends to 4 results, which is thin relative to catalogue breadth. Recorded determinations are mutually consistent. |
| Shandong Nuoweiou Medical Technology Co | B | 5 | At 5 determinations, sampling variation exceeds any effect the figures would show. Consistent across the whole evidence base. |
| PurePEPS | B | 4 | Submitted evidence extends to 4 results, which is thin relative to catalogue breadth. Internal consistency is not in question. |
| Rayshine Peptide Biochemicals | C | 6 | Submitted evidence extends to 6 results, which is thin relative to catalogue breadth. |
| HealthTide Biotech | C | 6 | 6 determinations permit an impression and do not permit an assessment. Determinations are genuine and low. |
| Dankang BioHealth | C | 12 | At 12 determinations, sampling variation exceeds any effect the figures would show. |
| Kits4less | C | 7 | 7 determinations permit an impression and do not permit an assessment. |
| Huayi Biotechnology | C | 19 | 19 determinations are held — adequate to characterise, short of the threshold for assessment. The recorded band sits beneath the assessment range. |
| Anlv Biotechnology | C | 10 | At 10 determinations, sampling variation exceeds any effect the figures would show. Determinations fall below the range occupied by assessed suppliers. |
| Xingtai Pukelai Technology Co | C | 6 | 6 determinations permit an impression and do not permit an assessment. |
| EHZ Peptides | C | 39 | 39 determinations are held — adequate to characterise, short of the threshold for assessment. |
| Zztai Peptide | C | 30 | At 30 determinations the central tendency is estimable and the interval is wide. Determinations fall below the range occupied by assessed suppliers. |
| Chimera Peptides | C | 8 | Submitted evidence extends to 8 results, which is thin relative to catalogue breadth. Placed below the assessment band on evidence rather than on reputation. |
| Hangzhou Mandy Biotechnology | C | 14 | 14 determinations constitute a working sample rather than a testing history. Determinations fall below the range occupied by assessed suppliers. |
| Yabang Peptide | C | 10 | Submitted evidence extends to 10 results, which is thin relative to catalogue breadth. |
| Evolve BioPep | C | 7 | 7 determinations permit an impression and do not permit an assessment. Below the threshold on the evidence held. |
| Quenna PMQ | D | 15 | Submitted evidence extends to 15 results and remains open. Determinations fall below the range occupied by assessed suppliers. The material submitted consists of images of certificates without a retrievable original, which the Institute records but cannot verify. |
| Nanjing Xiyuxun Technology XYX | D | 3 | The evidence base comprises 3 independent determinations, which is insufficient to support any criterion. Placed below the assessment band on evidence rather than on reputation. The submitted documentation reports a figure without the method that produced it, and a purity figure without its method is not comparable with any other. |
| Welon Peptide Solutions | D | 5 | 5 determinations are held, below the minimum the rubric requires for a dossier. The documentation accompanying the submitted results does not identify the batch, so no result can be tied to material a purchaser would receive. |
| Xingtai Lesda Technology | E | 6 | The evidence base comprises 6 results and is classified as insufficient. Determinations are genuine and low. Determinations are recorded below the range occupied by every supplier the Institute has assessed, and the documentation does not explain the difference. |
| Qingdao Hongshengda Trading | E | 4 | The evidence base comprises 4 results and is classified as insufficient. The material submitted consists of images of certificates without a retrievable original, which the Institute records but cannot verify. |
| ZZQ Peptides | E | 22 | 22 determinations constitute a working sample rather than a testing history. Where a result was queried, no supporting record was produced, so the determination stands unexplained rather than disputed. |
| Changan District Sheng Peptide Trading | E | 7 | Submitted evidence extends to 7 results, which is thin relative to catalogue breadth. The recorded band sits beneath the assessment range. |
| UWA Elite Peptides | E | 16 | 16 determinations constitute a working sample rather than a testing history. Determinations are genuine and low. The material submitted consists of images of certificates without a retrievable original, which the Institute records but cannot verify. |
| Hangzhou Youngpeptide Biotechnology HYB | E | 15 | At 15 determinations the central tendency is estimable and the interval is wide. Below the threshold on the evidence held. The documentation does not stand on its own: the figures cited are reproduced from a source the Institute could not retrieve. |
| Modern Aminos | E | 4 | 4 determinations permit an impression and do not permit an assessment. The recorded band sits beneath the assessment range. |
| Shanghai OuDaXin New Material Technology Center | E | 43 | The evidence base comprises 43 results. Volume is not the limiting factor. Placed below the assessment band on evidence rather than on reputation. Nothing in the submitted material names the laboratory that produced the determinations, which is the condition on which an independent result carries weight. |
| Shenzhen Jiechuang Trading | E | 8 | Submitted evidence extends to 8 results, which is thin relative to catalogue breadth. The submitted documentation reports a figure without the method that produced it, and a purity figure without its method is not comparable with any other. |
| Shaanxi Dideu Medichem | E | 6 | 6 determinations permit an impression and do not permit an assessment. The recorded band sits beneath the assessment range. |
| Qingdao VitaConin International Trading | E | 5 | 5 determinations permit an impression and do not permit an assessment. Below the threshold on the evidence held. Where a result was queried, no supporting record was produced, so the determination stands unexplained rather than disputed. |
| Guangzhou Lengiuanhuang Cosmetics | E | 4 | 4 determinations permit an impression and do not permit an assessment. The documentation accompanying the submitted results does not identify the batch, so no result can be tied to material a purchaser would receive. |
| Shanghai JinBei Chemical Technology | B | 18 | Submitted evidence extends to 18 results and remains open. No determination in the set is inconsistent with another. |
| Peptide Technologies | B | 11 | 11 determinations permit an impression and do not permit an assessment. Internal consistency is not in question. |
| Pura Peptides | X | 1 | The evidence base comprises a single independent determination, which is insufficient to support any criterion. No certainty band, there being no evidence base to assign one to. |
| Peptide Partners | B to C | 64 | 64 determinations are held, sufficient for characterisation on this criterion. Dispersion is the finding. |
| Bfflist AMO | B to C | 63 | The evidence base comprises 63 results. Volume is not the limiting factor. Determinations span more than one band. |
| Pure Tested Peptides | B to C | 7 | 7 determinations are held, below the minimum the rubric requires for a dossier. The spread across recorded determinations is wider than the spread within any single assessed supplier in the Institute’s set. |
| PeptiSlim | C to E | 38 | 38 determinations constitute a working sample rather than a testing history. Dispersion exceeds what analytical variation accounts for. |
| Glamgurcraft Innovations Foreign Trade | X | 1 | A single result is held; the rubric cannot be applied to it. Unrated. The evidence will not support a band. |
| HkRoids | B to C | 14 | The evidence base comprises 14 results and has not stabilised. Between-lot variance dominates the central estimate. Consistency, not level, is the material question here: the best recorded result would sit comfortably among the assessed set and the worst would not. |
| Yiwu Aozuo Trading Co | B to E | 91 | At 91 determinations the sample is adequate and the conclusion turns on dispersion. |
| Peptide Haven | B | 4 | 4 determinations permit an impression and do not permit an assessment. No determination in the set is inconsistent with another. |
| Atomik Labz | B to C | 40 | Submitted evidence extends to 40 results and remains open. Dispersion exceeds what analytical variation accounts for. |
| Bulk Peptide Supply | B to E | 20 | Submitted evidence extends to 20 results and remains open. Dispersion exceeds what analytical variation accounts for. |
| M-Peptides | B to C | 17 | 17 determinations constitute a working sample rather than a testing history. Dispersion exceeds what analytical variation accounts for. |
| Mai Peptide | C to E | 55 | The evidence base comprises 55 results. Volume is not the limiting factor. Determinations range across bands, which characterises the process. |
| Peptidology | B | 16 | 16 determinations are held — adequate to characterise, short of the threshold for assessment. |
| Hazel | X | 1 | A single determination is on record. The Institute does not assess on that basis. No band is assigned; the Institute does not impute one. |
| TCI | X | 1 | A single determination is on record. The Institute does not assess on that basis. Unrated. The evidence will not support a band. |
| Uther | B to E | 69 | Submitted evidence extends to 69 results across multiple catalogue lines. Dispersion exceeds what analytical variation accounts for. |
| Shandong Shengyuan Peptide Technology | B to E | 24 | The evidence base comprises 24 results and has not stabilised. Between-lot variance dominates the central estimate. The spread across recorded determinations is wider than the spread within any single assessed supplier in the Institute’s set. |
| LiliPeptide | C to E | 185 | 185 determinations constitute a substantial evidence base; dispersion rather than location is the material question. Dispersion exceeds what analytical variation accounts for. |
| Xingruida XDR | B to D | 64 | 64 determinations are held, sufficient for characterisation on this criterion. Determinations span more than one band. |
| Eternal Peptides | B | 23 | 23 determinations constitute a working sample rather than a testing history. Recorded determinations are mutually consistent. |
| Tianjin Ruiwang New Material Technology Co | B to E | 107 | Submitted evidence extends to 107 results across multiple catalogue lines. A range is reported rather than a point because the evidence supports one. Reporting a single band would conceal the fact that matters most about it. |
| Polaris Peptides | B to D | 97 | 97 determinations are held, sufficient for characterisation on this criterion. Recorded determinations span more than one band, which is a statement about the process rather than about any one lot. |
| Injectify | B to E | 29 | At 29 determinations the central tendency is estimable and the interval is wide. Determinations span more than one band. |
| Precision Peptide Co | B to C | 21 | Submitted evidence extends to 21 results and remains open. Dispersion is the finding. |
| AKS Chem | X | 1 | The evidence base comprises a single independent determination, which is insufficient to support any criterion. No band is assigned; the Institute does not impute one. |
| Reta-Peptide | B to E | 144 | 144 determinations constitute a substantial evidence base; dispersion rather than location is the material question. Dispersion exceeds what analytical variation accounts for. |
| Peptide-S | B to E | 125 | At 125 determinations the sample is adequate and the conclusion turns on dispersion. Between-lot variance dominates the central estimate. |
| Planet Peptide | B to D | 59 | The evidence base comprises 59 results. Volume is not the limiting factor. The spread across recorded determinations is wider than the spread within any single assessed supplier in the Institute’s set. |
| Henan Sahe Peptide | B to D | 18 | 18 determinations constitute a working sample rather than a testing history. Determinations range across bands, which characterises the process. |
| Hunan Ruiwang Technology Center | B to C | 14 | At 14 determinations the central tendency is estimable and the interval is wide. Determinations range across bands, which characterises the process. |
| Skye Peptides | B to E | 73 | At 73 determinations the sample is adequate and the conclusion turns on dispersion. Dispersion exceeds what analytical variation accounts for. |
| Nuscience Peptides | B to D | 47 | At 47 determinations the sample is adequate and the conclusion turns on dispersion. Dispersion is the finding. |
| NextechLabs | B to D | 30 | 30 determinations constitute a working sample rather than a testing history. Dispersion exceeds what analytical variation accounts for. |
| Golden Eagle | B to C | 17 | Submitted evidence extends to 17 results and remains open. A range is reported rather than a point because the evidence supports one. Reporting a single band would conceal the fact that matters most about it. |
| Peptide Worldwide | X | 1 | The evidence base comprises a single independent determination, which is insufficient to support any criterion. No band. The rubric requires an evidence base before it can be applied, and there is not one here. |
| HK Peptides | B to E | 343 | Submitted evidence extends to 343 results across multiple catalogue lines. Between-lot variance dominates the central estimate. The band is reported as a range because the underlying determinations occupy one, and a purchaser buys a lot rather than a distribution. |
| Nexaph | B to E | 200 | 200 determinations constitute a substantial evidence base; dispersion rather than location is the material question. Dispersion exceeds what analytical variation accounts for. |
| BeiBangAn | C to D | 38 | 38 determinations are held — adequate to characterise, short of the threshold for assessment. Between-lot variance dominates the central estimate. The band is reported as a range because the underlying determinations occupy one, and a purchaser buys a lot rather than a distribution. |
| Shandong Aishi Biotechnology | D to E | 37 | 37 determinations constitute a working sample rather than a testing history. Recorded determinations span more than one band, which is a statement about the process rather than about any one lot. |
| Xingtai Jiachuang Technology | C to E | 31 | Submitted evidence extends to 31 results and remains open. Determinations range across bands, which characterises the process. |
| Zenith Jove Peptide ZJ | B to E | 26 | At 26 determinations the central tendency is estimable and the interval is wide. Determinations range across bands, which characterises the process. |
| Kerisite Shenzhen International | B to D | 16 | The evidence base comprises 16 results and has not stabilised. The results do not sit in a single band. The Institute records the range rather than the midpoint, because a midpoint describes no lot that was actually tested. |
| YB Peptide | B to E | 10 | At 10 determinations, sampling variation exceeds any effect the figures would show. Determinations at the top and the bottom of the recorded range differ by more than the analytical method would account for. |
| Qing Li Peptide | B to E | 260 | Submitted evidence extends to 260 results across multiple catalogue lines. Dispersion is the finding. |
| Shanxi Qianyecao Biotech QYC | D to E | 66 | 66 determinations constitute a substantial evidence base; dispersion rather than location is the material question. Dispersion exceeds what analytical variation accounts for. |
| Verified Peptides | B to C | 34 | 34 determinations constitute a working sample rather than a testing history. Determinations span more than one band. |
| Hebei Rimao Technology | C to D | 32 | Submitted evidence extends to 32 results and remains open. Determinations range across bands, which characterises the process. |
| Pure Rawz | B to D | 29 | The evidence base comprises 29 results and has not stabilised. Determinations span more than one band. |
| Heman Peptide HM | B to E | 29 | 29 determinations are held — adequate to characterise, short of the threshold for assessment. Dispersion exceeds what analytical variation accounts for. |
| Shanghai Baoju | B to E | 21 | The evidence base comprises 21 results and has not stabilised. Dispersion is the finding. |
| ZLZ Peptide | B to E | 199 | At 199 determinations the sample is adequate and the conclusion turns on dispersion. Determinations range across bands, which characterises the process. |
| Peptide Sciences | B to E | 123 | 123 determinations constitute a substantial evidence base; dispersion rather than location is the material question. Determinations span more than one band. |
| Allen Biotechnology Co ABC | B to E | 43 | The evidence base comprises 43 results. Volume is not the limiting factor. Determinations range across bands, which characterises the process. |
| Peptide Crafters | B to D | 39 | At 39 determinations the central tendency is estimable and the interval is wide. Determinations span more than one band. |
| Simple Peptide | B to D | 26 | The evidence base comprises 26 results and has not stabilised. Dispersion exceeds what analytical variation accounts for. |
| Top Peptide | C to D | 21 | 21 determinations constitute a working sample rather than a testing history. Recorded determinations span more than one band, which is a statement about the process rather than about any one lot. |
| Zen Peptides | B to C | 13 | Submitted evidence extends to 13 results and remains open. A range is reported rather than a point because the evidence supports one. Reporting a single band would conceal the fact that matters most about it. |
| Amino Lair | B to D | 12 | Submitted evidence extends to 12 results, which is thin relative to catalogue breadth. Between-lot variance dominates the central estimate. Recorded determinations span more than one band, which is a statement about the process rather than about any one lot. |
| Oupeptide | B to E | 149 | At 149 determinations the sample is adequate and the conclusion turns on dispersion. |
| Paramount Peptides | B to E | 65 | 65 determinations are held, sufficient for characterisation on this criterion. Determinations span more than one band. |
| Yimei | B to E | 54 | At 54 determinations the sample is adequate and the conclusion turns on dispersion. Dispersion is the finding. |
| LSPL | C to E | 40 | At 40 determinations the central tendency is estimable and the interval is wide. The band is reported as a range because the underlying determinations occupy one, and a purchaser buys a lot rather than a distribution. |
| Royal Peptides | B to C | 30 | At 30 determinations the central tendency is estimable and the interval is wide. Dispersion is the finding. |
| Shenzhen Loga Tech LG LOGA | B to E | 21 | The evidence base comprises 21 results and has not stabilised. Results range across bands. Where that is so, an average is the least informative summary available and none is given. |
| ZhuoYan lab | C to E | 30 | 30 determinations are held — adequate to characterise, short of the threshold for assessment. The band is reported as a range because the underlying determinations occupy one, and a purchaser buys a lot rather than a distribution. |
| Astro Peptides | B to E | 29 | Submitted evidence extends to 29 results and remains open. Between-lot variance dominates the central estimate. The spread across recorded determinations is wider than the spread within any single assessed supplier in the Institute’s set. |
| Mix Peptides | D to E | 29 | At 29 determinations the central tendency is estimable and the interval is wide. Dispersion exceeds what analytical variation accounts for. |
| Science | B to C | 12 | 12 determinations are held, below the minimum the rubric requires for a dossier. Determinations at the top and the bottom of the recorded range differ by more than the analytical method would account for. |
| TSC Top Supplements China | C to E | 99 | 99 determinations constitute a substantial evidence base; dispersion rather than location is the material question. Dispersion exceeds what analytical variation accounts for. |
| HXNet | C to E | 91 | At 91 determinations the sample is adequate and the conclusion turns on dispersion. Between-lot variance dominates the central estimate. |
| Xian Yihang Technology | C to E | 48 | The evidence base comprises 48 results. Volume is not the limiting factor. Determinations span more than one band. |
| Haikou Mingheng Technology | B to C | 16 | The evidence base comprises 16 results and has not stabilised. Dispersion exceeds what analytical variation accounts for. |
| SRY Labs | B to E | 111 | 111 determinations are held, sufficient for characterisation on this criterion. Results range across bands. Where that is so, an average is the least informative summary available and none is given. |
| Accelerate Labs | B to E | 20 | At 20 determinations the central tendency is estimable and the interval is wide. Dispersion exceeds what analytical variation accounts for. |
| PurePeptides | B to E | 15 | Submitted evidence extends to 15 results and remains open. Between-lot variance dominates the central estimate. Consistency, not level, is the material question here: the best recorded result would sit comfortably among the assessed set and the worst would not. |
| Regenerative Research | X | 2 | 2 determinations are on record. The Institute does not assess on that basis. No certainty band, there being no evidence base to assign one to. |
| Zhejiang Yichenkang Biotechnology | B to E | 58 | Submitted evidence extends to 58 results across multiple catalogue lines. Between-lot variance dominates the central estimate. The band is reported as a range because the underlying determinations occupy one, and a purchaser buys a lot rather than a distribution. |
| Biolongevity Labs | B to E | 33 | Submitted evidence extends to 33 results and remains open. The results do not sit in a single band. The Institute records the range rather than the midpoint, because a midpoint describes no lot that was actually tested. |
| Alpha-Gen | B to E | 30 | Submitted evidence extends to 30 results and remains open. Dispersion exceeds what analytical variation accounts for. |
| LN Peptides | B to E | 28 | The evidence base comprises 28 results and has not stabilised. Between-lot variance dominates the central estimate. Consistency, not level, is the material question here: the best recorded result would sit comfortably among the assessed set and the worst would not. |
| Forever Young Pharmacy | B to E | 26 | 26 determinations constitute a working sample rather than a testing history. Determinations span more than one band. |
| Prime Peptides | B to E | 19 | 19 determinations are held — adequate to characterise, short of the threshold for assessment. Determinations range across bands, which characterises the process. |
| Haikou Mingheng Biotechnology | D to E | 11 | 11 determinations are held, below the minimum the rubric requires for a dossier. Determinations range across bands, which characterises the process. |
| Dragon Pharma | X | 1 | Submitted evidence extends to 1 result and no dossier has been opened. No certainty band, there being no evidence base to assign one to. |
| Liberty Peptides | B to E | 16 | The evidence base comprises 16 results and has not stabilised. Between-lot variance dominates the central estimate. The spread across recorded determinations is wider than the spread within any single assessed supplier in the Institute’s set. |
| Amino Asylum | B to C | 15 | Submitted evidence extends to 15 results and remains open. A range is reported rather than a point because the evidence supports one. Reporting a single band would conceal the fact that matters most about it. |
| Amino Amigos | B to E | 37 | At 37 determinations the central tendency is estimable and the interval is wide. Determinations at the top and the bottom of the recorded range differ by more than the analytical method would account for. |
| Platinum Cryo | B to E | 24 | At 24 determinations the central tendency is estimable and the interval is wide. Between-lot variance dominates the central estimate. A range is reported rather than a point because the evidence supports one. Reporting a single band would conceal the fact that matters most about it. |
| Elite Research USA | B to E | 47 | The evidence base comprises 47 results. Volume is not the limiting factor. Determinations range across bands, which characterises the process. |
| Limitless Life Nootropics | B to D | 22 | At 22 determinations the central tendency is estimable and the interval is wide. Determinations at the top and the bottom of the recorded range differ by more than the analytical method would account for. |
| Oasis Peptides | B to E | 16 | Submitted evidence extends to 16 results and remains open. Between-lot variance dominates the central estimate. The band is reported as a range because the underlying determinations occupy one, and a purchaser buys a lot rather than a distribution. |
| Suaway Lab Research | B to E | 39 | The evidence base comprises 39 results and has not stabilised. Dispersion is the finding. |
| Pharma Grade Peptides | B to E | 18 | At 18 determinations the central tendency is estimable and the interval is wide. Consistency, not level, is the material question here: the best recorded result would sit comfortably among the assessed set and the worst would not. |
| PeptiLab Research | B to E | 15 | 15 determinations constitute a working sample rather than a testing history. Determinations span more than one band. |
| Tydes | C to E | 41 | 41 determinations are held, sufficient for characterisation on this criterion. The band is reported as a range because the underlying determinations occupy one, and a purchaser buys a lot rather than a distribution. |
| Loti Labs | B to E | 32 | 32 determinations constitute a working sample rather than a testing history. Recorded determinations span more than one band, which is a statement about the process rather than about any one lot. |
| Wolverine Peptides | X | 1 | A single result is held; the rubric cannot be applied to it. No band is assigned; the Institute does not impute one. |
| Amplified Amino | C to E | 12 | 12 determinations are held, below the minimum the rubric requires for a dossier. Dispersion exceeds what analytical variation accounts for. |
| Alimo Peptide | D to E | 7 | The evidence base comprises 7 results and is classified as insufficient. Dispersion exceeds what analytical variation accounts for. |
| Richards Biotech Simply Richards | X | 1 | A single result is held; the rubric cannot be applied to it. No band. The rubric requires an evidence base before it can be applied, and there is not one here. |
| Coastal Peptides | B to E | 26 | 26 determinations constitute a working sample rather than a testing history. Between-lot variance dominates the central estimate. The results do not sit in a single band. The Institute records the range rather than the midpoint, because a midpoint describes no lot that was actually tested. |
| Peptides 4 Research | C to E | 20 | At 20 determinations the central tendency is estimable and the interval is wide. Between-lot variance dominates the central estimate. The results do not sit in a single band. The Institute records the range rather than the midpoint, because a midpoint describes no lot that was actually tested. |
| Deuschem | B to E | 29 | The evidence base comprises 29 results and has not stabilised. Between-lot variance dominates the central estimate. Determinations at the top and the bottom of the recorded range differ by more than the analytical method would account for. |
| Hybiopeptides | X | 1 | Submitted evidence extends to 1 result and no dossier has been opened. No band. Recorded as an absence rather than estimated. |
| Peptide Gurus | B to E | 45 | At 45 determinations the sample is adequate and the conclusion turns on dispersion. Determinations span more than one band. |
| Swiss Chems | C to E | 9 | The evidence base comprises 9 results and is classified as insufficient. A range is reported rather than a point because the evidence supports one. Reporting a single band would conceal the fact that matters most about it. |
| WllyBIO | X | 1 | Submitted evidence extends to 1 result and no dossier has been opened. Deliberately unassigned. |
| Biolabshop Limited | C to E | 6 | The evidence base comprises 6 results and is classified as insufficient. Dispersion exceeds what analytical variation accounts for. |
| Peptides For Sale | D to E | 21 | Submitted evidence extends to 21 results and remains open. Consistency, not level, is the material question here: the best recorded result would sit comfortably among the assessed set and the worst would not. |
| NuLife Peptides | B | 6 | The evidence base comprises 6 results and is classified as insufficient. Consistent across the whole evidence base. |
| Wuhan Newtop Biotech | X | 2 | At 2 determinations the evidence base is below the minimum for assessment. No band. Recorded as an absence rather than estimated. |
| LOOKBiotech | X | 2 | Submitted evidence extends to 2 results and no dossier has been opened. No certainty band, there being no evidence base to assign one to. |
| PRIVATE | X | 2 | Submitted evidence extends to 2 results and no dossier has been opened. No band. Recorded as an absence rather than estimated. |
| Peptide Ark | X | 2 | 2 results are held; the rubric cannot be applied to them. No certainty band, there being no evidence base to assign one to. |
| Zhuoyue Biotechnology | X | 1 | Submitted evidence extends to 1 result and no dossier has been opened. Recorded as unrated. This is a statement about what the Institute holds and not about the supplier. |
| Hebei Chengtong Technology | X | 1 | At 1 determination the evidence base is below the minimum for assessment. No band. The rubric requires an evidence base before it can be applied, and there is not one here. |
| Coffee and Peppers | X | 1 | A single result is held; the rubric cannot be applied to it. No certainty band, there being no evidence base to assign one to. |
| Marvel Peptide | X | 1 | At 1 determination the evidence base is below the minimum for assessment. Deliberately unassigned. |
| HK Fat Cat | X | 1 | A single determination is on record. The Institute does not assess on that basis. No certainty band, there being no evidence base to assign one to. |
| Guangzhou Yuao Trading | X | 1 | At 1 determination the evidence base is below the minimum for assessment. No band is assigned; the Institute does not impute one. |
| PepKits | X | 1 | At 1 determination the evidence base is below the minimum for assessment. No certainty band, there being no evidence base to assign one to. |
| Lejian Biotech Peptide | X | 1 | A single determination is on record. The Institute does not assess on that basis. Deliberately unassigned. |
| PepLab Solutions | X | 1 | A single determination is on record. The Institute does not assess on that basis. |
| Explicit Sarms | X | 1 | At 1 determination the evidence base is below the minimum for assessment. No band. Recorded as an absence rather than estimated. |
| Weifang Xingbei International Trade | X | 1 | The evidence base comprises a single independent determination, which is insufficient to support any criterion. No band. Recorded as an absence rather than estimated. |
| Advanced Technology and Industrial | X | 1 | The evidence base comprises a single independent determination, which is insufficient to support any criterion. Deliberately unassigned. |
Appearing here records what the Institute could not obtain. It is not an adverse finding and should not be read as one.
Dossiers
28 documents · page 1 of 2
-
Certificates that carry the counter-ion as a figure with its unit, on every line sampled. One of the longer-established active-ingredient houses in the assessment set, and the only one whose research-catalogue certificates report the counter-ion as a figure with its unit as standard rather than on…
96.0 / 100A -
The oldest filing in this set, and the only one publishing four independent reports against a single lot rather than one report against a sample. Every certificate examined carried the method line, the itemised related substances and the…
98.0 / 100A -
Handling and shipment documentation, including stated conditions for lyophilised presentations. Handling documentation is among the better examples in the set. Shipment conditions are stated for lyophilised presentations rather than left to be assumed, and the storage statement is compound-specific…
82.0 / 100A -
Certificates restate the requested sequence, which is a real control against sequence ambiguity. The only supplier in the assessment set whose certificates routinely restate the sequence as ordered, which is a meaningful control where an investigational compound has more than one sequence in circulation…
96.0 / 100A -
Batch traceability: the certificate number and the vial label agree, line after line. Batch traceability is among the better examples in the set. Certificate batch numbers corresponded to vial labelling on every sampled line, which is the precondition for a certificate meaning anything at all…
83.0 / 100A -
Independent reporting at a frequency few in the set match. Independent reporting frequency is among the highest in the set: reports were obtainable for the principal lines on every sampling occasion, each attributable to a named laboratory. Documentation is consistent…
85.0 / 100A -
Certificates that carry the column, the gradient and the water determination, on every line sampled. One of the longer-established synthesis houses in the assessment set, and one of the few whose research-catalogue certificates carry the counter-ion figure and the integration conditions as issued rather than…
94.0 / 100A -
Orthogonal identity confirmation, including amino-acid analysis on request. Identity-confirmation practice is among the strongest in the assessment set, and this is the only supplier for which amino-acid analysis was offered in response to an Institute enquiry. High-resolution mass…
83.0 / 100A -
The incretin lines are documented per batch, end to end, including cold chain. On the incretin range this is the most completely documented supplier in the Institute's set: per-batch independent reporting, mass-spectrometric identity for semaglutide and tirzepatide against stated…
95.0 / 100A -
Certificates in one consistent form, which makes comparison across lines quick. Documentation is consistent in form across every line sampled, which aids comparison and makes an anomaly easy to see. Purity, method and identity are all carried on the certificate, and independent reports…
83.0 / 100A -
A warehouse network that puts stock in the purchaser’s own jurisdiction. A distribution-led operation with regional stock in six jurisdictions, which shortens transit and keeps a lot out of long-haul conditions. Certificate completeness and identity practice both score at the top…
84.0 / 100A -
A documented warehouse network, with the dispatching point named on the record. A distribution-led operation whose warehouse network is documented rather than merely asserted: the dispatching point is named on the order record, which is what allows a transit history to be reconstructed at…
82.0 / 100A -
Certificates that reproduce the chromatogram behind the purity figure, on every line sampled. The distinguishing feature of this supplier’s documentation is that the chromatogram is on the certificate. Where the rest of the assessment set reports a purity figure and asks the reader to accept it, this…
96.0 / 100A -
Independent reporting present across the range sampled, with the laboratory named. Independent reporting is present across the range sampled and each report names the laboratory that produced it, which is the condition on which an independent result carries weight. Certificates carry purity…
82.0 / 100A -
A worldwide stocking network with the method now named on the certificate. A research-peptide operation working through a worldwide stocking network. Certificates in the current cycle name the chromatographic method alongside the purity figure, which is what makes a purity figure…
82.0 / 100A -
Life-science reagent documentation conventions, applied consistently across the catalogue. Documentation follows established life-science reagent conventions more closely than most of the set, which is an advantage in format as well as in content: a reader who has handled a reagent certificate can…
91.0 / 100A -
Complete certificates from a newer operation, consistent from the first cycle assessed. A newer operation whose certificates carry the critical fields in full from the first cycle in which it was assessed: purity with the method named, identity by mass spectrometry, and peptide content…
85.0 / 100A -
Documentation that improved measurably between cycles, and kept the improvement. Documentation improved measurably between the two assessment cycles in which this supplier has been reviewed, principally through the addition of mass-spectrometric identity to certificates, and the…
85.0 / 100A -
Independent per-batch reporting concentrated on the incretin lines. Certificate completeness and identity practice score at the top of the set on the lines sampled, and independent reports were obtainable per batch for the incretin range. Documentation is legible and…
88.0 / 100A -
Certificates that carry the counter-ion and the water determination, on every line sampled. One of the longest-established manufacturers in the assessment set, and one of the few whose research-catalogue certificates carry a counter-ion identity and content and a water determination as a matter of…
95.0 / 100A
page 1 of 2